Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update.

Document Type

Article

Publication Date

3-1-2020

Institution/Department

Maine Medical Center Research Institute

Journal Title

The Journal of clinical endocrinology and metabolism

MeSH Headings

Humans, Female, Postmenopause, Osteoporosis, Bone Density Conservation Agents

Abstract

OBJECTIVE: The objective is to provide an update of the 2019 Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline for the pharmacological management of osteoporosis in postmenopausal women using romosozumab.

CONCLUSIONS: We reviewed findings from the meta-analysis and primary clinical trials assessing the efficacy of romosozumab, a monoclonal antibody targeting sclerostin, for the prevention of fractures and concluded that this agent can be considered a treatment option for postmenopausal women at very high risk for osteoporotic fracture. The romosozumab label has a boxed warning, recommending careful consideration by the treating clinician as to cardiovascular risk profile in the individual woman who might receive this agent, since clinical trial data from an active comparator study show an imbalance in serious cardiovascular adverse events between romosozumab and alendronate.

ISSN

1945-7197

Link to Full Text

Share

COinS